These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
438 related articles for article (PubMed ID: 33114553)
1. Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics. Gavriilaki M; Kimiskidis VK; Gavriilaki E Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114553 [TBL] [Abstract][Full Text] [Related]
2. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum. Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917 [TBL] [Abstract][Full Text] [Related]
3. Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. Chamberlain JL; Huda S; Whittam DH; Matiello M; Morgan BP; Jacob A J Neurol; 2021 May; 268(5):1643-1664. PubMed ID: 31482201 [TBL] [Abstract][Full Text] [Related]
4. Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders. Miyamoto K; Minamino M; Kuwahara M; Tsujimoto H; Ohtani K; Wakamiya N; Katayama KI; Inoue N; Ito H Front Immunol; 2023; 14():1090548. PubMed ID: 36936980 [TBL] [Abstract][Full Text] [Related]
5. The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders. Stathopoulos P; Dalakas MC Expert Rev Clin Immunol; 2022 Sep; 18(9):933-945. PubMed ID: 35899480 [TBL] [Abstract][Full Text] [Related]
6. Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder. Dodig D; Genge A; Selchen D; Freedman MS Can J Neurol Sci; 2023 Mar; 50(2):165-173. PubMed ID: 34895385 [TBL] [Abstract][Full Text] [Related]
7. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Hakobyan S; Luppe S; Evans DR; Harding K; Loveless S; Robertson NP; Morgan BP Mult Scler; 2017 Jun; 23(7):946-955. PubMed ID: 27613120 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System. Carpanini SM; Torvell M; Morgan BP Front Immunol; 2019; 10():362. PubMed ID: 30886620 [TBL] [Abstract][Full Text] [Related]
17. [Analysis of the application of glucocorticoids in eight pediatric neurological disorders in China]. ; ; Zhonghua Er Ke Za Zhi; 2021 Oct; 59(10):847-852. PubMed ID: 34587681 [No Abstract] [Full Text] [Related]
18. Hematopoietic stem cell transplantation for uncommon immune-mediated neurological disorders: A literature review. Jaime-Pérez JC; Meléndez-Flores JD; Ramos-Dávila EM; González-Treviño M; Gómez-Almaguer D Cytotherapy; 2022 Jul; 24(7):676-685. PubMed ID: 35193829 [TBL] [Abstract][Full Text] [Related]
19. Plasmapheresis in neurological disorders: six years experience from University Clinical center Tuzla. Sinanović O; Zukić S; Burina A; Pirić N; Hodžić R; Atić M; Alečković-Halilović M; Mešić E F1000Res; 2017; 6():1234. PubMed ID: 28928949 [TBL] [Abstract][Full Text] [Related]
20. Peripheral memory B cells in multiple sclerosis vs. double negative B cells in neuromyelitis optica spectrum disorder: disease driving B cell subsets during CNS inflammation. Tieck MP; Vasilenko N; Ruschil C; Kowarik MC Front Cell Neurosci; 2024; 18():1337339. PubMed ID: 38385147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]